Stocktoria
BIOGEN INC. BIIB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1991-09-17
BIOGEN INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | — | — | 25.9% |
| Net margin | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% |
| FCF margin | 20.7% | 28.1% | 12.9% | 11.2% | 30.8% |
| Return on assets | 4.4% | 5.8% | 4.3% | 12.4% | 6.5% |
| Return on equity | 7.1% | 9.8% | 7.8% | 22.7% | 14.2% |
| Debt / equity | 0.34× | 0.27× | 0.46× | 0.47× | 0.57× |
| Current ratio | 2.68 | 1.35 | 2.00 | 2.99 | 1.83 |
| Revenue growth | 2.2% | -1.6% | -3.3% | -7.4% | -18.3% |
Source: SEC EDGAR filings · CIK 0000875045 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.